CTSHIV: a knowledge-based system for the management of HIV-infected patients
暂无分享,去创建一个
[1] E. De Clercq,et al. Antiviral therapy for human immunodeficiency virus infections , 1995, Clinical microbiology reviews.
[2] J W Mulder,et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. , 1996, The Journal of infectious diseases.
[3] Peter Jackson,et al. Introduction to expert systems , 1986 .
[4] D. Richman,et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[5] D. Katzenstein,et al. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. , 1993, Journal of acquired immune deficiency syndromes.
[6] S D Kemp,et al. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture , 1991, Journal of virology.
[7] S D Kemp,et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.
[8] S D Kemp,et al. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. , 1991, AIDS.
[9] S D Kemp,et al. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.
[10] S. Dewhurst,et al. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine , 1995, Journal of clinical microbiology.
[11] T. Chou,et al. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. , 1996, AIDS research and human retroviruses.
[12] S W Tu,et al. AIDS2: a decision-support tool for decreasing physicians' uncertainty regarding patient eligibility for HIV treatment protocols. , 1993, Proceedings. Symposium on Computer Applications in Medical Care.
[13] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[14] Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1990, Disease markers.
[15] M A Wainberg,et al. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. , 1994, Leukemia.
[16] M A Wainberg,et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine , 1992, Journal of virology.
[17] T. Merigan,et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. , 1992, The New England journal of medicine.
[18] J. Lange,et al. Triple combinations: present and future. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[19] S. Frost,et al. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection , 1994, AIDS.